`
`M;id|s:;o.='1, WI b3';'[]Il -51 I8
`
`Perklnsijc-ae.u:om
`
`February 26, 2016
`
`VIA E-MAIL
`
`John T. Bennett
`
`Goodwin Procter LLP
`
`Exchange Place
`Boston, MA 02109
`
`David L. Anstactt
`DAI1stactt@perkinscoic_com
`o.
`(503) 663-5408
`F.
`(608) 663-7499
`
`Re:
`
`In re Copaxone 40 mg Consolidated Cases, C.A. No. 14-117] —GMS (Consolidated)
`
`Dear John:
`
`I write regarding several discovery issues.
`
`First, Plaintiffs appear to have marked the entire deposition transcripts of Irit Pinchasi
`and a third-party witness, Dr. Jerry Wolinsky, as outside counsel eyes only under the protective
`order. However, plaintiffs have no genuine basis for making such a sweeping confidentiality
`designation under the protective order. At a minimum, the following sections should not be
`designated confidential under the protective order, either Highly Confidential or Outside Counsel
`Only: 2;’!5f2016 Wolinsky Dep. Tr. at 12:10-13:7, 35:15-38:25, 42:6-44:6, 64:22-65:13, 63:3-
`I6, 69:14-25, 167320-171:1], 222:l3—224:l4, and 237:l7—238:5; 2/1122016 Pir1chasiDep. Tr. at
`12:18~13:3, 15:2-19:24, and 152:5-153116. Please confirm that these sections are not Highly
`Confidential or Outside Counsel Only by Tuesday, March 1, 2016. More broadly, please also
`provide appropriately limited confidentiality designation.s—if any—for
`the Pinchasi and
`Wolinsky deposition transcripts.
`
`
`
`MYLAN PHARMS. INC. EXHIBIT 1143 PAGE 1
`
`
`
`John T. Bennett
`
`February 26, 2016
`Page 2
`
`
`
`David L. Anstaeti
`
`DLA:krd
`
`i~‘:arkim [Iuia LLP
`
`MYLAN PHARMS. INC. EXHIBIT 1143 PAGE 2